Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)

Conclusions. SL8 seems highly effective and safe in well-selected HCV-monoinfected and HIV-HCV–coinfected patients in a real-world setting.

Source: Clinical Infectious Diseases - October 27, 2016 Category: Infectious Diseases Authors: Ingiliz, P., Christensen, S., Kimhofer, T., Hueppe, D., Lutz, T., Schewe, K., Busch, H., Schmutz, G., Wehmeyer, M. H., Boesecke, C., Simon, K.-G., Berger, F., Rockstroh, J. K., zur Wiesch, J. S., Baumgarten, A., Mauss, S. Tags: ARTICLES AND COMMENTARIES Source Type: research